JP2018523673A5 - - Google Patents

Download PDF

Info

Publication number
JP2018523673A5
JP2018523673A5 JP2018507602A JP2018507602A JP2018523673A5 JP 2018523673 A5 JP2018523673 A5 JP 2018523673A5 JP 2018507602 A JP2018507602 A JP 2018507602A JP 2018507602 A JP2018507602 A JP 2018507602A JP 2018523673 A5 JP2018523673 A5 JP 2018523673A5
Authority
JP
Japan
Prior art keywords
hcab
pdgf
seq
amino acid
specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018507602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523673A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/046595 external-priority patent/WO2017030909A1/en
Publication of JP2018523673A publication Critical patent/JP2018523673A/ja
Publication of JP2018523673A5 publication Critical patent/JP2018523673A5/ja
Pending legal-status Critical Current

Links

JP2018507602A 2015-08-14 2016-08-11 Pdgfに対する重鎖のみ抗体 Pending JP2018523673A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562205191P 2015-08-14 2015-08-14
US62/205,191 2015-08-14
US201662333772P 2016-05-09 2016-05-09
US62/333,772 2016-05-09
PCT/US2016/046595 WO2017030909A1 (en) 2015-08-14 2016-08-11 Heavy chain only antibodies to pdgf

Publications (2)

Publication Number Publication Date
JP2018523673A JP2018523673A (ja) 2018-08-23
JP2018523673A5 true JP2018523673A5 (enExample) 2019-08-22

Family

ID=56740535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018507602A Pending JP2018523673A (ja) 2015-08-14 2016-08-11 Pdgfに対する重鎖のみ抗体

Country Status (7)

Country Link
US (5) US10308711B2 (enExample)
EP (1) EP3334762A1 (enExample)
JP (1) JP2018523673A (enExample)
AU (1) AU2016307943A1 (enExample)
CA (1) CA2992788A1 (enExample)
HK (1) HK1254093A1 (enExample)
WO (1) WO2017030909A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
RU2749674C2 (ru) * 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-vegf 항체
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
MXPA05002841A (es) 2002-09-18 2005-05-27 Oculex Pharm Inc Metodo y aparato de administracion de implantes oculares.
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
EP4353819A3 (en) 2004-07-22 2024-07-17 Erasmus University Medical Center Rotterdam Binding molecules
US8466263B2 (en) * 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
TWI404727B (zh) 2006-01-25 2013-08-11 荷蘭鹿特丹Erasmus大學醫學中心 對偶基因排除
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
SI2274008T1 (sl) 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
PL2606070T3 (pl) * 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CA2849508C (en) * 2011-09-30 2020-12-22 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
WO2014072876A1 (en) 2012-11-09 2014-05-15 Pfizer Inc. Platelet-derived growth factor b specific antibodies and compositions and uses thereof
US9428577B2 (en) * 2012-11-09 2016-08-30 Pfizer Inc. Platelet-derived growth factor B specific antibodies and compositions and uses thereof
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
RU2749674C2 (ru) * 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь

Similar Documents

Publication Publication Date Title
JP2016504416A5 (enExample)
JP2018527327A5 (enExample)
JP2010528047A5 (enExample)
RU2014113046A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
JP2020114218A5 (enExample)
JP2019515027A5 (enExample)
AU2011201340B2 (en) Novel anti-PIGF antibody
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
JP2020079246A5 (enExample)
RU2015121755A (ru) Антагонисты ил-6 и их применение
JP2011504872A5 (enExample)
JP2013528607A5 (enExample)
JP2020515545A5 (enExample)
JP2017535285A5 (enExample)
HRP20211641T1 (hr) Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
JP2014532072A5 (enExample)
JP2017534646A5 (enExample)
RU2014129316A (ru) Способы ингибирования глазного ангиогенеза
NZ574308A (en) Scfv antibodies which pass epithelial and/or endothelial layers
RU2018103960A (ru) Антитела против ang-2, содержащие только тяжелую цепь
JP2018510617A5 (enExample)
JP2012165745A5 (enExample)
JP2017515811A5 (enExample)
JP2018530574A5 (enExample)
HRP20251312T1 (hr) Poboljšana protutijela za il-6